Article Text

other Versions

PDF
Synovial immunopathological changes associated with successful abatacept therapy in a case of severe refractory psoriatic arthritis
  1. Juan D Cañete (jcanete{at}clinic.ub.es)
  1. Hospital Clinic, Spain
    1. Raquel Celis, PhD (rcelis{at}jet.es)
    1. Hospital Clinic, Spain
      1. M Victoria Hernández (mvhernandez{at}clinic.ub.es)
      1. Hospital Clinic, Spain
        1. José L Pablos (jlpablos{at}clinic.ub.es)
        1. Hospital 12 de octubre, Spain
          1. Raimon Sanmartí (sanmarti{at}clinic.ub.es)
          1. Hospital Clinic, Spain

            Abstract

            T-cells and proinflammatory cytokines seem to play important roles in the pathogenesis of psoriatic arthritis (PsA). TNF-α antagonists have shown remarkable therapeutic efficacy, reducing the progression of bone damage and improving the quality of life of PsA patients. A significant number of PsA patients do not respond or are intolerant to these therapies and require alternatives. Drugs interfering with T cell activation have shown variable effects in PsA. We describe a PsA patient with moderate-to-severe skin and nail disease, and severe polyarthritis refractory to anti-TNF therapy, which were successfully treated with abatacept. Synovial tissue cellular changes and changes in synovial fluid cytokines after 24 weeks of abatacept therapy are described. The excellent clinical response in our patient was paralleled by a reduction in synovial neutrophils, macrophages, and T-cells, and a substantial reduction in interferon-gamma and pro-inflammatory cytokine levels

            Statistics from Altmetric.com

            Request permissions

            If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.